Invivyd, Inc. (IVVD) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Invivyd, Inc. is a biopharmaceutical company focused on developing monoclonal antibodies (mAbs) for viral infectious diseases, primarily SARS-CoV-2. The company received Emergency Use Authorization (EUA) from the FDA in March 2024 for PEMGARDA (pemivibart) for pre-exposure prophylaxis of COVID-19 in immunocompromised patients. In July 2024, the company submitted a request to amend the EUA to include treatment of mild-to-moderate symptomatic COVID-19. The company also initiated a Phase 1 clinical trial for its next-generation candidate, VYD2311, in September 2024.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $9,300 | $0 | $11,564 | $0 |
| Net Loss | $(60,739) | $(39,440) | $(151,482) | $(124,989) |
| Loss Per Share (Basic/Diluted) | $(0.51) | $(0.36) | $(1.28) | $(1.14) |
| Research & Development Expenses | $57,850 | $25,574 | $119,344 | $96,393 |
| Selling, General & Admin Expenses | $12,955 | $12,886 | $48,973 | $34,038 |
| Cash and Cash Equivalents (End of Period) | $106,869 | $181,822 | $106,869 | $181,822 |
| Net Cash Used in Operating Activities (9M) | $(132,881) | $(113,924) | $(132,881) | $(113,924) |
Liquidity & Debt: As of September 30, 2024, the company held $106.9 million in cash and cash equivalents. There is no long-term debt reported. The company has an accumulated deficit of $883.6 million.
Material Changes vs. Prior Period
- Revenue Generation: The company generated $9.3 million in revenue for Q3 2024, compared to zero in Q3 2023, driven by the commercial launch of PEMGARDA following its March 2024 EUA.
- Expense Increases: R&D expenses increased significantly by $32.3 million in Q3 2024 (vs. Q3 2023), primarily due to the nomination and development costs of the new candidate VYD2311 ($45.0 million in direct costs) and commercial manufacturing costs for PEMGARDA. SG&A expenses remained relatively flat quarter-over-quarter but increased $14.9 million on a nine-month basis due to commercialization costs and accelerated stock-based compensation for the former CEO.
- Inventory Capitalization: Beginning in March 2024, the company began capitalizing inventory costs for PEMGARDA rather than expensing them as R&D. Management noted that if pre-EUA manufacturing costs had been capitalized, reported gross margins would approach 80%.
- Cash Burn: Cash and cash equivalents decreased by approximately $93.8 million during the nine months ended September 30, 2024, compared to an increase of $89.7 million in the same period in 2023 (driven by marketable securities maturities in 2023).
Guidance, Outlook, Risks, and Contingencies
- Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern. Based on current operating plans and excluding future revenues or external financing, the company does not have sufficient cash to fund operations beyond one year from the issuance of these financial statements.
- Guidance Withdrawal: In October 2024, the company withdrew its formal revenue guidance for FY2024. This decision followed growth headwinds caused by confusion in the healthcare provider community regarding PEMGARDA's neutralization activity against certain SARS-CoV-2 variants (specifically KP.3.1.1) after the FDA updated the PEMGARDA Fact Sheet to include contested third-party data.
- Regulatory & Commercial Risks: The company faces risks related to the FDA's reliance on third-party virologic data which may differ from the company's internal data. Additionally, the EUA for PEMGARDA is contingent on the declaration of a public health emergency and the prevalence of variants with reduced susceptibility to the drug.
- Capital Needs: The company expects to require additional funding through a combination of product revenues, equity offerings, debt financings, or strategic collaborations to support ongoing operations and development.
Key Facts for Investor Verification
- Cash Runway: Verify the company's ability to secure additional capital given the "substantial doubt" going concern disclosure and the current cash balance of $106.9 million.
- Revenue Sustainability: Assess the impact of the withdrawn FY2024 guidance and the FDA's updated Fact Sheet on future PEMGARDA sales volumes and market acceptance.
- Variant Susceptibility: Monitor ongoing data regarding PEMGARDA's neutralization activity against emerging SARS-CoV-2 variants (e.g., KP.3.1.1, LB.1) and the FDA's response to such data.
- Development Progress: Track the timeline and preliminary data readouts for the VYD2311 Phase 1 trial, expected late in Q4 2024, as a potential future revenue driver.
- Contractual Obligations: Note the $38.3 million in remaining contractually binding commercial manufacturing obligations to WuXi Biologics due in 2024 and 2025.